The UK Competition Authority accepts the commitments of a pharmaceutical company to continue supplying a bipolar medicine to the national market (Essential Pharma)

On 18 December 2020, the UK Competition and Markets Authority (“CMA”) announced that it had accepted Essential Pharma’s commitments to continue supplying a bipolar medicine to the UK market. Essential Pharma is a supplier of both Priadel and Camcolit, long-term treatments for individuals suffering from bipolar disorder. In October 2020, the CMA opened an investigation examining whether Essential Pharma may have abused its dominant position in relation to the supply of Priadel and/ or Camcolit in the UK. The specific conduct under scrutiny was Essential Pharma’s proposal to discontinue the supply of Priadel

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Van Bael & Bellis (Brussels)

Quotation

Samuel Hall, The UK Competition Authority accepts the commitments of a pharmaceutical company to continue supplying a bipolar medicine to the national market (Essential Pharma), 18 December 2020, e-Competitions January 2021, Art. N° 98573

Visites 163

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues